Literature DB >> 9988795

Telomerase activity in complete hydatidiform mole.

S N Bae1, S J Kim.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the association of telomerase activity in complete hydatidiform moles with subsequent development of persistent gestational trophoblastic tumor. STUDY
DESIGN: By means of the standard telomerase repeat assay, we examined telomerase activity in 4 normal placentas, 31 complete hydatidiform moles (16 cases of uneventful regression, according to serum levels of beta-human chorionic gonadotropin, after evacuation and 15 cases in which persistent gestational trophoblastic disease developed after evacuation), 7 invasive moles, and 5 choriocarcinoma tissue samples.
RESULTS: Telomerase activity was detected in 13 of 15 (86.7%) complete hydatidiform moles in patients who eventually underwent chemotherapy for the treatment of persistent gestational trophoblastic tumors. All 9 patients with metastatic disease (International Federation of Gynecology and Obstetrics stage III) had telomerase activity in the initial molar tissue sample. In contrast, telomerase activity was evident in only 3 of 16 (12.5%) complete hydatidiform moles from patients with spontaneous remission after evacuation (P <.05). Telomerase activity was detected in all 7 invasive moles and all 5 choriocarcinoma tissue samples but was not detected in normal placentas.
CONCLUSION: The presence of telomerase activity in complete hydatidiform moles is associated with the development of persistent gestational trophoblastic tumors, such as invasive moles and choriocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988795     DOI: 10.1016/s0002-9378(99)70208-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  1 in total

1.  LPCAT1-TERT fusions are uniquely recurrent in epithelioid trophoblastic tumors and positively regulate cell growth.

Authors:  Gavin R Oliver; Sofia Marcano-Bonilla; Jonathan Quist; Ezequiel J Tolosa; Eriko Iguchi; Amy A Swanson; Nicole L Hoppman; Tanya Schwab; Ashley Sigafoos; Naresh Prodduturi; Jesse S Voss; Shannon M Knight; Jin Zhang; Numrah Fadra; Raul Urrutia; Michael Zimmerman; Jan B Egan; Anthony G Bilyeu; Jin Jen; Ema Veras; Rema'a Al-Safi; Matthew Block; Sarah Kerr; Martin E Fernandez-Zapico; John K Schoolmeester; Eric W Klee
Journal:  PLoS One       Date:  2021-05-25       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.